Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial

Name: Αlpha¹ Rigor Record — Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial
Item: Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial
Rating: 94
Author: Αlpha¹

Martin CK, Carmichael OT, Carnell S, Considine RV, Kareken DA, Dydak U, Mattes RD, Scott D, Shcherbinin S, Nishiyama H, Knights A, Urva S, Biernat L, Pratt E, Haupt A, Mintun M, Otero Svaldi D, Milicevic Z, Coskun T.

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.75★ (Adequate), 0 critical, 1 high issue for “Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.75 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.

Problems surfaced4 types

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted, transparently reported phase 1 randomized partially-blinded trial of tirzepatide, with strong reporting across nearly all eight rigor dimensions: a clear premise, rigorous design (randomization, blinding, a priori power analysis), full biological-variable reporting, named IRB approvals, identified investigational products, and detailed statistical reporting with all recomputed tests consistent. The one substantive gap is the data/code availability dimension, where no analysis code is shared (only managed patient-data access via Vivli), and a handful of minor reporting polish items remain (sex-imbalance context, analyst blinding, CONSORT naming, ANCOVA assumptions).

Two independent reviewer runs (same model) each scored all eight dimensions; they agreed on seven and split only on data code availability (pass vs warn, over whether code sharing is applicable) — the synthesis lands on warn. N/A sub-criteria (cell lines, antibodies, mycoplasma, organisms, reproduction, IACUC, repository deposit/accession numbers) were excluded from scoring. Machine verification was partial: 6 statistics recomputed (all consistent), 57 references checked (0 retracted, 0 not found), 2 reproducibility links live, and 8 claims audited (0 under-evidenced); the limited statistics coverage does not license any claim of global statistical correctness.

8 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 6 tests: 6 consistent, 0 inconsistent; 6 via agent-written checks.

Reporting

Eight Dimensions7 pass · 1 warn

Prior work on GLP-1 RAs and tirzepatide is cited, with acknowledgment of their limitations (e.g., 'these studies used limited measures of ingestive behavior and did not collect brain functioning measurements'). The hypothesis follows logically from the premise. Limitations of prior research are explicitly addressed in the introduction and discussion.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper clearly establishes the scientific foundation by citing prior work on GLP-1 RAs and tirzepatide, providing a logical rationale for the study, and addressing gaps in prior research.

Evidence

direct quote[Introduction, paragraphs 1-3]

“Previous studies of selective glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) using self-report inventories suggest these therapies affect ingestive behaviors”